Edmonton scientists gave Cold-fX a booster shot yesterday, pumping the maker of the illness-fighting pill to a 5.68% gain on the stock market. CV Technologies (TSXV:CVQ) shares on the Canadian Venture Exchange closed at 93 cents each, up five cents, after the announcement yesterday that regular usage of Cold-fX may reduce cold or flu incidence. Cold-fX underwent a 323-participant, one-year clinical trial by University of Alberta biochemist Tapan Basu and Capital Health medical officer of health Gerry Predy. The study was completed under Health Canada’s new Natural Health Product regulations. Each participant was instructed to take two capsules a day of Cold-fX or a placebo for a period of four months during the winter of 2003-04. Results suggested a 26% reduction in the average number and frequency of cold infections per person in the Cold-fX group. Recurrent infection (additional illness) was reduced 56%. Moreover, there was a 45% reduction in the total number of cold days suffered per participant and a 31% reduction in the severity of their symptoms.
